Seres Therapeutics is a clinical-stage company that has identified conditions raising substantial doubt about its ability to continue as a going concern. The company reported 10,195,031 shares of common stock outstanding as of November 2, 2026, and is seeking additional funding or strategic partnerships to advance its SER-155 clinical programs.
Seres Therapeutics reported Q3 2026 financial results and announced plans to advance SER-155 into a study for the prevention of immune checkpoint inhibitor-related enterocolitis (irEC). The company expects to submit the study design to the FDA in Q1 2027 following positive investigator-sponsored trial results showing an 80% clinical response rate.
Term
Q3 2026
“The irEC IST provided promising evidence that orally administered SER-155 improved epithelial barrier integrity and reduced gastrointestinal inflammation without systemic immunosuppression and was well-tolerated in patients with ICI-induced enterocolitis.”
Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres
“We believe SER-155 may enable ICI patients, of whom there are currently estimated to be approximately 300,000 in the U.S. alone, to remain on their therapy by reducing the occurrence of irEC, which often requires the halting of life-saving cancer treatment.”
Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres